Considering the available therapeutic options, the need for an alternative efficient therapy is overwhelming.
More attention should be given to patients with frequent attacks in order to provide them more efficient therapy.
Introduction The Veno-Arterial ExtraCorporeal Life Support (VA-ECLS) is an efficient therapy in refractory cardiogenic shock.
Each of these applications demands materials with specific physical, chemical, biological, biomechanical and degradation properties to provide efficient therapy.
Defects in mitochondrial DNA often cause neuromuscular pathologies, for which no efficient therapy has yet been developed.
Astute investigation on engineered MSCs may lead to a new avenue toward an efficient therapy for patients with cancer.
In contrast, closed-loop systems adapt therapy in response to physiological changes and may provide more effective and efficient therapy.
Therefore, prognostic markers for the development of sepsis attach importance to start an efficient therapy as early as possible.
A clinical confirmation of these data will hopefully help advance a more efficient therapy of neuroendocrine tumors with less off-target effects in the future.
Unfortunately no efficient therapy exists that can tackle all of these symptoms while at the same time delaying or preventing cell death.
Extracorporeal life support (ECLS) seems an efficient therapy for acute, potentially reversible cardiac or respiratory failure, when conventional therapy has been inadequate, or as bridge to transplant, but there is no evidence for cost-effectiveness.
